Justdapa-V 10/100 Tablet SR is a combination oral antidiabetic medication containing Dapagliflozin 10 mg and Vildagliptin 100 mg, formulated as a sustained-release tablet. It is indicated for the management of type 2 diabetes mellitus in adults to improve glycemic control when diet and exercise alone are insufficient. Dapagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, reduces renal glucose reabsorption, promoting urinary glucose excretion and thereby lowering blood glucose levels. Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances incretin hormone activity, increasing insulin secretion and decreasing glucagon release in a glucose-dependent manner. The sustained-release formulation ensures a gradual release of active ingredients, contributing to improved patient compliance and steady plasma drug concentrations. Justdapa-V 10/100 Tablet SR should be used with caution in patients with renal impairment, and it is contraindicated in individuals with type 1 diabetes or diabetic ketoacidosis. Common adverse effects may include urinary tract infections, genital infections, and gastrointestinal disturbances. Regular monitoring of renal function and glycemic parameters is recommended during therapy. This combination therapy offers a complementary mechanism of action targeting multiple pathophysiological defects in type 2 diabetes, facilitating effective glycemic control.